Journal
INFECTIOUS DISEASES AND THERAPY
Volume 2, Issue 2, Pages 123-144Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s40121-013-0009-3
Keywords
Antitubercular agents; Bedaquiline; Drug-resistant tuberculosis; Extensively drug-resistant; Multidrug-resistant tuberculosis; Tuberculosis; TMC207
Categories
Funding
- National Health and Medical Research Council of Australia [APP1054107]
Ask authors/readers for more resources
Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial limitations, in terms of their effectiveness, side-effect profile, and complexity of administration. Bedaquiline is a novel diarylquinoline antibiotic that has recently been investigated as an adjunct to existing therapies for MDR-TB. Currently, limited clinical data are available to evaluate the drug's safety and effectiveness. In two small randomized-controlled clinical studies, bedaquiline given for 8 or 24 weeks has been shown to improve surrogate microbiological markers of treatment response, but trials have not yet evaluated its impact on clinical failure and relapse. Safety concerns include an increased mortality in the bedaquiline arm of one study, an increased incidence of QT segment prolongation on electrocardiogram, and hepatotoxicity. Until further research data are available, the use of bedaquiline should be confined to settings where carefully selected patients can be closely monitored.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available